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Radical surgery for mesothelioma
The epidemic is still to peak and we need more research to manage it
One in every hundred men born in the 1940swill die of die of malignant pleural mesothe-lioma, which is almost exclusively a conse-
quence of exposure to asbestos, with a lag time that is
rarely less than 25 years and often more than 50 years
from first exposure. Half of all cases are now aged over
70, with 80% in men. For a man first exposed as a teen-
ager, who remained in a high risk occupation, such as
insulation, throughout his working life, the lifetime risk
of mesothelioma can be as high as one in five.w1 There
are now over 1800 deaths per year in Britain (about
one in 200 of all deaths in men and one in 1500 in
women), and the number is still increasing.1 w2 As expo-
sure in the United Kingdom continued until 1980 the
peak of the epidemic is still to come, and we need a
strategy to manage these patients.
Asbestos was a valuable and versatile material and
imports rose after the second world war when it was
widely used as an insulator, in the manufacture of
filters, cements, friction products, and as a fire
retardant. It found a place in shipbuilding and industry
and was used extensively in building in the form of
light workable boards.2 It was a convenient partitioning
material that combined insulation and fire proofing.
The Health and Safety Executive statistics indicate that
25% of deaths will be in men who worked in the build-
ing industry and that carpenters and joiners are most
commonly afflicted.w3 These men have often been self
employed in small enterprises or engaged in do it
yourself home improvements. About 90% of deaths
due to mesothelioma are due to exposure to asbestos
in unmonitored settings. Wives and daughters who
washed the overalls of asbestos workers are among
those who have died.
Imports were at their highest from about 1955 to
1980 in the UK.3 The Asbestos Licensing Regulations
came into force in the United Kingdom in 1983 and
Control of Asbestos at Work Regulations in 1987 (both
amended in 1988). The peak of the epidemic is
expected in 2015 to 2020 when the death rate is likely
to be 2000 per year in the United Kingdom. The situa-
tion in Europe is similar.4 Australia had the highest pro
rata asbestos usage,w4 and asbestos imports continue in
the developing world.w5 The epidemic in the United
States has probably peaked because of earlier
awareness and action on asbestos imports.5 Many
countries are seeing the rising tide of an epidemic, and
all doctors need to know how to recognise and
diagnose this disease and what treatments are
available.6
Mesothelioma is a relatively slow growing tumour
that most commonly originates in the parietal pleura
but can also arise in the abdomen and the tunica vagi-
nalis. It presents with pain in the chest wall or
breathlessness due to increased pleural fluid, but
symptoms may be absent or develop insidiously. Not
infrequently, at the time of first awareness, a thick rim
(1 cm or more) of hard dense tumour encasing and
restricting the lung may already be present. The
diagnosis can be difficult to prove. When pleural
disease is found it has to be distinguished from pleural
plaques and malignant effusion from adenocarci-
noma.6 Cytological examination of pleural fluid and
small needle biopsies are often inconclusive because
adequate tissue is required and it may take several
attempts, culminating in surgical biopsy—each time
with a risk of infection and needle or drain track seed-
ing to which mesothelioma is particularly prone.
Biopsy and drain tract radiotherapy is recommended.6
Once made there is tendency for the diagnosis to
be met with a sense of hopelessness—not without good
reason for it is a horrible disease, often with months of
unremitting pain, progressively diminishing pulmo-
nary performance, cachexia, and the inevitability of
death. Median survival from diagnosis is usually under
a year, but individual series vary markedly7 8 as is not
surprising in a cancer with such a long lead time and in
which the known phase of the disease is a small
proportion of its natural history.
How can we think about it positively? The best we
can offer at present is stage specific treatments, which
should whenever possible be within clinical trials.
As with most solid tumours the first consideration
is surgery—can we cut it out and get rid of it? The
operation, extrapleural pneumonectomy, entails
removal of all the parietal pleura, the pericardium, and
the diaphragm in addition to the whole lung on that
side.9 It is usually considered as part of trimodality
treatment with various combinations of preoperative
and postoperative chemotherapy and radiotherapy to
the empty hemithorax after surgery.10 This is associated
with survival figures of up to 48% at five years in highly
selected subsets of patients with the more favourable
epithelioid (as opposed to sarcomatoid) histology and
no lymph node metastases.w6-w9 Radical surgery has
been performed infrequently in the United Kingdom,
with an average of only 20 patients per year in the past
Additional references w1-w3 appear on bmj.com
Saturday 31 January 2004
BMJ
BMJ 2004;328:237–8
237BMJ VOLUME 328 31 JANUARY 2004 bmj.com
five years. Some patients and their doctors desperately
seek radical surgery as their only hope, but others have
doubts about the evidence.11 A trial is needed, and a
pilot feasibility study (the mesothelioma and radical
surgery “MARS” trial, funded by Cancer Research UK)
is now under way. To answer the question 670 patients
will be required over three years with five years’ follow
up. If achieved this would give an answer by about 2012
in time for the peak of the epidemic.
Irrespective of whether radical surgery will be con-
sidered much needs to be done in the care of these
patients. The diagnosis should be made early and effi-
ciently. Without it we cannot have meaningful
discussions with the patient or plan treatment, and the
patient’s legal position in terms of compensation
remains unclear. At the same time we try to control any
pleural effusion to maintain breathing as long as possi-
ble.6 This is best done by thoracoscopic talc
pleurodesis, which can usefully be combined with sur-
gical biopsy. Then with the diagnosis made the disease
can be staged. If the pathological stage is early extra-
pleural pneumonectomy should be considered, and we
would recommend that this is done in the context of
multimodality treatment and within a study.11 If the
tumour is inoperable management can be with
chemotherapy, and again it would be preferable that
this is within a study.12
This disease is increasing in frequency. There is
nothing we can do now to prevent it in workers exposed
to asbestos throughout the 1950s, 1960s, and 1970s.
What we can do is recognise it early, treat it actively, and
learn about best treatment with carefully thought out
studies because we will be seeing many more
mesotheliomas in the next 25 years. In the developed
world alone 100 000 people alive now will die from it.
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Pandemic risks from bird flu
The risk to humans is small, but we need to be better prepared
An outbreak of avian influenza is ravaging thepoultry industry in South East Asia. Thiscarries a devastating economic toll for the
communities affected, but what of the associated risk to
human health? At least seven people in Vietnam have
been infected by the strain of H5N1 subtype influenza
found in poultry. Of these six are dead. In Thailand
three boys contracted the virus; two are dead. These
numbers are small, and investigations and case studies
so far suggest that the virus does not transmit from
human to human but is acquired directly from close
contact with infected chickens. How likely is it that
these events signify the emergence of a new human
pandemic, and what measures do we have to deal with
the global threat?
Although we think of influenza as a human disease,
the natural reservoir for influenza A viruses is aquatic
birds and wildfowl. Many different strains circulate at
any one time, and most are not associated with disease
in wild birds. Influenza strains are divided into subtypes
depending on the antigenic nature of the H (haemag-
glutinin) and N (neuraminidase enzyme) proteins. A
limited subset of influenza subtypes H1N1, H3N2, and
H1N2 cause annual epidemics in humans, but all had
their origins in avian species. They adapted for
transmission in people following zoonotic events.
Influenza virus has several options for creating genetic
diversity. Firstly, it can shuffle genetic material derived
from two different virus sources in an event known as
reassortment. This was certainly the origin of the influ-
enza pandemic strains of 1957 and 1968. Secondly,
being composed of ribonucleic acid rather than
deoxyribonucleic acid, influenza virus is error prone.
Stepwise single mutations accumulate, and these can
eventually alter the properties of the virus. This
happened early after the H3N2 virus was introduced
into the human population in 1968. Some changes
occurred during replication of avian viruses in people
during zoonotic events in Hong Kong in 1997, where
six of 18 infected individuals died,1 and in the fatal case
of a veterinarian infected during a poultry epidemic of
H7N7 influenza in the Netherlands last year, although
these changes were luckily not sufficient to allow trans-
mission between people.
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